Agenus Announces Virtual Annual Shareholders Meeting

Rhea-AI Summary

Agenus, a leading immuno-oncology company, has announced its Annual Shareholders Meeting will be held virtually on June 11, 2024, at 10:30 a.m. ET. Registration starts at 10:15 a.m. ET. Shareholders can participate by visiting www.virtualshareholdermeeting.com/AGEN2024 and entering a 16-digit control number from their proxy materials. Guests can listen without a control number. Agenus focuses on cancer immunotherapy using a broad range of antibody therapeutics, adoptive cell therapies, and adjuvants. The company is headquartered in Lexington, MA, and more information can be found at www.agenusbio.com.

Positive

• Virtual format allows broader access to shareholders.
• Meeting scheduled for June 11, 2024, well in advance, providing ample notice.
• Focus on cancer immunotherapy, a growing and high-impact field.
• Utilization of a broad repertoire of therapeutic approaches, enhancing the potential for treatment success.

Negative

• Virtual-only format may reduce engagement for shareholders who prefer in-person meetings.
• No new financial or clinical updates provided in the announcement, limiting information on the company's progress.
• Potential technical issues with virtual meetings could hinder participation.

LEXINGTON, Mass.--(BUSINESS WIRE)-- Agenus Inc. (“Agenus”) (NASDAQ: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that its Annual Shareholders Meeting will begin at 10:30 a.m. ET on June 11, 2024, and will be conducted in a virtual format only. Registration for attendees will start at 10:15 a.m. ET.

To participate in the Annual Shareholders Meeting, shareholders should visit www.virtualshareholdermeeting.com/AGEN2024 and enter the 16-digit control number found in their proxy materials. Guests may also access the Annual Shareholders Meeting, but in listen-only mode. No control number is required for guests.

Webcast Information:

Date: Tuesday, June 11, 2024

Time: 10:30 a.m. ET

A live webcast and replay will be accessible on the Company’s website at https://investor.agenusbio.com/events-and-presentations and at www.virtualshareholdermeeting.com/AGEN2024.

About Agenus

Agenus is a leading immuno-oncology company targeting cancer and infectious diseases with a comprehensive pipeline of immunological agents. The company’s mission is to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus is headquartered in Lexington, MA. For more information, visit www.agenusbio.com or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240604262147/en/

Investor

917-362-1370

investor@agenusbio.com



Media

612-839-6748

communications@agenusbio.com

Source: Agenus Inc.

FAQ

When is the Agenus virtual Annual Shareholders Meeting?

The Agenus virtual Annual Shareholders Meeting is on June 11, 2024, at 10:30 a.m. ET.

How can shareholders participate in the Agenus Annual Shareholders Meeting?

Shareholders can participate by visiting www.virtualshareholdermeeting.com/AGEN2024 and entering their 16-digit control number from proxy materials.

Can guests attend the Agenus Annual Shareholders Meeting?

Yes, guests can attend in listen-only mode without a control number.

What is the focus of Agenus as a company?

Agenus focuses on discovering and developing immunological agents to treat cancers and infectious diseases.

Where is Agenus headquartered?

Agenus is headquartered in Lexington, MA.